Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114


VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.

Tyler RK, Shpiro N, Marquez R, Eyers PA.

Cell Cycle. 2007 Nov 15;6(22):2846-54. Epub 2007 Aug 27.


Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.

Xu DR, Huang S, Long ZJ, Chen JJ, Zou ZZ, Li J, Lin DJ, Liu Q.

J Transl Med. 2011 May 21;9:74. doi: 10.1186/1479-5876-9-74.


Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells.

Pan C, Yan M, Yao J, Xu J, Long Z, Huang H, Liu Q.

Oral Oncol. 2008 Jul;44(7):639-45. Epub 2007 Nov 8.


Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.

Kwiatkowski N, Deng X, Wang J, Tan L, Villa F, Santaguida S, Huang HC, Mitchison T, Musacchio A, Gray N.

ACS Chem Biol. 2012 Jan 20;7(1):185-96. doi: 10.1021/cb200305u. Epub 2011 Oct 21.


Validating Aurora B as an anti-cancer drug target.

Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, Taylor SS.

J Cell Sci. 2006 Sep 1;119(Pt 17):3664-75. Epub 2006 Aug 15.


Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks.

Scutt PJ, Chu ML, Sloane DA, Cherry M, Bignell CR, Williams DH, Eyers PA.

J Biol Chem. 2009 Jun 5;284(23):15880-93. doi: 10.1074/jbc.M109.005694. Epub 2009 Apr 9.


The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, Raynaud FI, Eccles SA, Chesler L, Linardopoulos S.

Mol Cancer Ther. 2011 Nov;10(11):2115-23. doi: 10.1158/1535-7163.MCT-11-0333. Epub 2011 Sep 1.


Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.

Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX, Liu Q.

Blood. 2008 Mar 1;111(5):2854-65. Epub 2007 Dec 26.


Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.

LeRoy PJ, Hunter JJ, Hoar KM, Burke KE, Shinde V, Ruan J, Bowman D, Galvin K, Ecsedy JA.

Cancer Res. 2007 Jun 1;67(11):5362-70.


Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias.

Fei F, Stoddart S, Groffen J, Heisterkamp N.

Mol Cancer Ther. 2010 May;9(5):1318-27. doi: 10.1158/1535-7163.MCT-10-0069. Epub 2010 Apr 13.


Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.

Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim DY, Kim DJ, Li X, Kang S, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z.

Cancer Res. 2013 Jan 15;73(2):716-24. doi: 10.1158/0008-5472.CAN-12-2784. Epub 2012 Nov 1.


Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL, Nguyen HN, Olivieri PR, Romero K, Schenkel LB, Bak A, Stanton M, Dussault I, Patel VF, Geuns-Meyer S, Radinsky R, Kendall RL.

Cancer Res. 2010 Dec 1;70(23):9846-54. doi: 10.1158/0008-5472.CAN-10-3001. Epub 2010 Oct 8.


Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Cheetham GM, Charlton PA, Golec JM, Pollard JR.

Cancer Lett. 2007 Jun 28;251(2):323-9. Epub 2007 Jan 19.


Trivalent dimethylarsenic compound induces histone H3 phosphorylation and abnormal localization of Aurora B kinase in HepG2 cells.

Suzuki T, Miyazaki K, Kita K, Ochi T.

Toxicol Appl Pharmacol. 2009 Dec 15;241(3):275-82. doi: 10.1016/j.taap.2009.08.017. Epub 2009 Aug 28.


Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells.

D'Alise AM, Amabile G, Iovino M, Di Giorgio FP, Bartiromo M, Sessa F, Villa F, Musacchio A, Cortese R.

Mol Cancer Ther. 2008 May;7(5):1140-9. doi: 10.1158/1535-7163.MCT-07-2051.


Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.

Glant TT, Besenyei T, Kádár A, Kurkó J, Tryniszewska B, Gál J, Soós G, Szekanecz Z, Hoffmann G, Block JA, Katz RS, Mikecz K, Rauch TA.

Arthritis Rheum. 2013 Jul;65(7):1725-35. doi: 10.1002/art.37986.


Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.

Kaestner P, Stolz A, Bastians H.

Mol Cancer Ther. 2009 Jul;8(7):2046-56. doi: 10.1158/1535-7163.MCT-09-0323. Epub 2009 Jul 7.


Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.

Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N.

Cell Cycle. 2009 Jun 15;8(12):1921-9. Epub 2009 Jun 15.


Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma.

Wan XB, Fan XJ, Chen MY, Xu J, Long ZJ, Hua YJ, Ji H, Liu L, Hong MH, Zeng YX, Liu Q.

Cancer Biol Ther. 2009 Aug;8(15):1500-6. Epub 2009 Aug 8.

Items per page

Supplemental Content

Write to the Help Desk